肝移植术后新发或合并恶性肿瘤患者化疗及靶向治疗的疗效与安全性

Efficacy and Safety of Chemotherapy and Targeted Therapy in Patients with New or Complicated Malignant Tumors After Liver Transplantation

目的总结分析7例肝移植后新发或合并恶性肿瘤患者化疗及靶向治疗的疗效与安全性。方法收集复旦大学附属中山医院肿瘤内科诊治的7例肝移植后新发或合并恶性肿瘤患者的临床资料及诊治过程,观察并分析疗效与不良反应情况。结果7例患者根据肿瘤病理类型、基因检测结果等选择化疗方案及靶向药物治疗,获得疾病控制,部分患者达到部分缓解,治疗不良反应以皮疹及消化道反应为主,未出现严重肝损及移植肝脏排斥反应,药物剂量下调后不良反应减轻。结论肝移植术后新发或合并恶性肿瘤患者,包括移植肝出现转移病灶,可以继续化疗和(或)联合分子靶向治疗,未见肝移植相关特殊并发症,肝移植状态可耐受化疗及靶向治疗。

Objective To summarize the efficacy and safety of chemotherapy and targeted therapy in seven patients with new or combined malignant tumor after liver transplantation.Methods Clinical data of 7 patients with new or complicated malignant tumor after liver transplantation were collected to observe and analyze the efficacy and adverse reactions.Results 7 patients were treated by chemotherapy and targeted drug therapy according to tumor pathological typed and genetic test results.Some patients achieved partial remission.The treatment adverse reactions were mainly rash and digestive tract reaction,no serious liver damage and transplanted liver rejection,and the adverse effects reducted after the drug dose reduction.Conclusion Patients with new or complicated malignant tumors after liver transplantation,including patients with liver metastases,can continue chemotherapy and/or combined molecular targeted therapy.Patients have no special complications related to liver transplantation,and liver transplantation status is still can resistant chemotherapy and targeted therapy.